TRIB
What one share of Trinity Biotech holds
In Vitro and In Vivo Diagnostic Substances
We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) in 2024, we have been developing a range of biosensor devices and related services, beginning with a continuous glucose monitoring (“CGM”) product.
Trinity Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $2.36 |
|---|---|
| Profit | −$2.01 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.32 |
| Cash and investments | $0.27 |
| Debt | $0.01 |
| Book value | −$3.85 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $18.28 | $3.98 | $1.29 | $1.11 | — | $46.17 |
| 2016 | $17.60 | −$17.78 | $0.74 | $1.06 | — | $23.67 |
| 2017 | $18.44 | −$7.49 | $0.90 | $0.82 | — | $13.56 |
| 2018 | $18.75 | −$4.27 | $1.45 | −$0.06 | — | $9.16 |
| 2019 | $17.75 | −$5.68 | $0.42 | $0.65 | — | $1.13 |
| 2022 | $15.72 | −$10.31 | $0.28 | −$0.51 | — | −$0.29 |
| 2023 | $7.42 | −$3.14 | $0.10 | −$1.61 | — | −$3.12 |
| 2024 | $3.43 | −$1.77 | $0.02 | −$0.26 | — | −$1.96 |
| 2025 | $2.36 | −$2.01 | $0.00 | −$0.32 | — | −$3.85 |